Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Day One Biopharmaceuticals (DAWN – Research Report) yesterday. The company’s ...

Ieq Capital LLC has reduced its stake in Regeneron Pharmaceuticals by 28%, selling 1,496 shares in the fourth quarter. Other ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss, 10 out of 11 have shown improvements after being treated with a gene therapy. “What is really ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

On February 18, 2025, a panel of the U.S. Court of Appeals for the First Circuit unanimously decided that in order to transform an ...

This was the stock's sixth consecutive day of gains.

The First Circuit has issued its long-anticipated opinion in United States v. Regeneron Pharmaceuticals, Inc., clarifying the ...

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA ...

On February 18, 2025, the United States Court of Appeals for the First Circuit issued its opinion in United States v.

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals with ...